Approved April 2018 only for treatment of hypercalcemia of malignancy in the setting of severe renal failure or for patients who are refractory to any bisphosphonate. Updated to biosimilar (Jubbonti(R) and Wyost(R)) in September 2025. 

• Micromedex Drug Information
• Micromedex Care Notes
• Drugs@FDA
• FDA Daily Med Package Inserts